Ibrutinib 140 Mg

Buy Ibrutinib 140 mg

Descriptions

Ibrutinib 140 Mg is a small-molecule inhibitor of BTK. Ibrutinib forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. BTK’s role in signaling through the B-cell surface receptors results in activation of pathways necessary for B-cell trafficking, chemotaxis, and adhesion. Nonclinical studies show that ibrutinib inhibits malignant B-cell proliferation and survival in vivo as well as cell migration and substrate adhesion in vitro.

To read more visit: Incepata pharma In bellow we have Presentation, Descriptions, Indications, Dosage & Administration, Side Effects, Precautions. Buy ibrutinib 140 mg (Ibrucent) only $246. To know more about the product visit Contact Us page.

Buy Ibrucent (Ibrutinib) 140 mg capsules 90’s Only $246

Presentation

Ibrucent 140: Each capsule contains Ibrutinib INN 140 mg

Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton’s tyrosine kinase. It is designated as a targeted covalent drug and it presents a very promising activity in B cell malignancies.⁴ Ibrutinib developed by Pharmacyclics Inc and in November 2013 was FDA-approved for the treatment of mantle cell lymphoma. February 2014, ibrutinib approved for the treatment of chronic lymphocytic leukemia and it indicate for the treatment of patients with Waldenström’s Macroglobulinemia. Ibrutinib has also approved by the EMA for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.

Indications

Ibrutinib, is a kinase inhibitor indicate for the treatment of patients with:

Mantle cell lymphoma (MCL) who have received at least one prior therapy. Accelerated approval was granted for this indication base on overall response rate. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trials.

Chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.

CLL with 17p deletion.

Waldenström’s macroglobulinemia (WM).

Dosage & Administration

MCL: 560 mg taken orally once daily (four 140 mg capsules once daily)
CLL and WM: 420 mg taken orally once daily (three 140 mg capsules once daily)
Capsules should take orally with a glass of water. The capsules should not opened, broke, or chewed

Side Effects

The most common adverse reactions (≥25%) in patients with B-cell malignancies (MCL, CLL, WM) were thrombocytopenia, neutropenia, diarrhea, anemia, fatigue, musculoskeletal pain, bruising, nausea, upper respiratory tract infection, and rash.

Precautions

Hemorrhage: Should monitor for bleeding
Infections: Patients should monitor for fever and infections and evaluate.
Cytopenias: Complete blood counts should check monthly.
Atrial Fibrillation: Patients should monitor for atrial fibrillation.
Second Primary Malignancies: Other malignancies occur in patients, including skin cancers, and other carcinomas.
Tumor Lysis Syndrome (TLS): Patients should monitor at risk for TLS (e.g. high tumor burden).
Embryo-Fetal Toxicity: Can cause fetal harm. Women should advise of the potential risk to a fetus and to avoid pregnancy while taking the drug.

Contraindications

None

Use in Pregnancy & Lactation

Pregnancy Category D

Based on animal data, Ibrutinib can cause fetal harm when administer to a pregnant woman. If this drug use during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should apprise of the potential hazard to the fetus.
It is not known whether Ibrutinib excrete in human milk. Because many drugs excrete in human milk and because of the potential for serious adverse reactions in nursing infants from Ibrutinib, a decision should made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

The safety and effectiveness of Ibrutinib in pediatric patients have not establish.

Geriatric Use

No overall differences in safety or effectiveness observe between elderly subjects and younger subjects. No overall differences in effectiveness observe between these patients and younger patients. Cardiac adverse events (atrial fibrillation and hypertension), infections (pneumonia, urinary tract infection and cellulitis) and gastrointestinal events (diarrhea and dehydration) occurred more frequently among elderly patients.

Drug Interaction

CYP3A Inhibitors: Co-administration with strong and moderate CYP3A inhibitors should avoid. If a moderate CYP3A inhibitor must use, Ibrutinib dose should reduce.
CYP3A Inducers: Co-administration with strong CYP3A inducers should avoid.
Commercial Packaging

Ibrucent 140: Each box contains 3 blister strips of 4 capsules
Ibrucent 140: Each bottle contains 90 capsules